In a report, a working group cautioned that the program must lessen its reliance on congressional appropriations or risk ...
FDA Expert Panel to Consider Limiting Gastric, Esophageal Cancer Immunotherapies to PD-L1 Expressors
The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.
NEW YORK – Bristol Myers Squibb and 2seventy bio said on Wednesday they are discontinuing enrollment in the Phase III KarMMa-9 study evaluating maintenance treatment with CAR T-cel therapy Abecma ...
The collaboration will focus on identifying protein biomarkers associated with immunotherapy response across cancer types.
As part of the deal, the companies said they will work together to advance gene therapies for diseases with high unmet medical need.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback